| ISPC 0.1365 17.17% | CTNT 0.0953 -40.73% | BYND 0.8226 5.19% | YXT 0.496 34.05% | TZA 5.08 -6.45% | EFOI 6.49 210.53% | TSLL 13.9 6.35% | NVDA 201.68 1.68% | BITO 10.63 2.71% | NFLX 97.31 -9.72% | INTC 68.5 0.00% | ZSPC 0.0536 -38.46% | TQQQ 58.59 3.83% | SOXS 18.87 -6.95% | TSLA 400.62 3.01% | XLE 55.02 -2.76% | AMC 1.86 15.53% | SCO 8.47 9.72% | PLUG 2.78 -2.80% | BMNG 1.6 4.58% | IBIT 43.94 2.83% | AAL 12.78 4.16% | BZAI 2.52 45.66% | CRML 12.56 35.49% | SOFI 19.43 2.10% | HIVE 2.51 14.87% | GRAB 4.21 4.73% | SPY 710.14 1.21% | SQQQ 56.39 -3.79% | SOXL 94.68 7.14% | SMR 12.65 10.87% | BMNR 22.95 2.27% | SNAP 6.03 0.17% | UCAR 1.49 29.57% | HIMS 28.82 6.78% | LZMH 0.1736 -84.07% | HYG 80.65 0.37% | DRIP 5.25 9.83% | ONDS 10 -1.96% | DVLT 0.758 -9.49% | AAPL 270.23 2.59% | QQQ 648.85 1.31% | MARA 11.6 0.43% | MSTR 166.52 11.80% | AMZN 250.56 0.34% | PLTR 146.39 2.54% | SPDN 9.13 -1.19% | PBM 7.6 29.47% | IONQ 46.09 3.16% | MSFT 422.79 0.60%

AtaiBeckley Inc. Reports Q4 2025 Earnings and Progress on BPL-003 Phase 3 Trials

AtaiBeckley Inc. (NASDAQ: ATAI) Reports Q4 2025 Results and Advances BPL-003 Toward Phase 3

AtaiBeckley Inc. (NASDAQ: ATAI) is a clinical-stage biotechnology company focused on innovative mental health treatments. Following its 2025 strategic combination and redomiciliation, the company is advancing key programs, including BPL-003 nasal spray for treatment-resistant depression (TRD).

Financial performance showed revenue growth to ~$1.07 million in Q4, with adjusted EPS beating estimates (though GAAP results reflected merger impacts). The company is on track to initiate a Phase 3 pivotal program for BPL-003 in Q2 2026, consisting of two trials (ReConnection-1 and ReConnection-2) targeting adults with TRD, following positive FDA End-of-Phase 2 feedback.

Despite ongoing unprofitability (negative P/E, negative operating cash flow), low debt and high liquidity support continued development. Other progress includes positive Phase 2a results for EMP-01 in Social Anxiety Disorder. The company discussed these updates during its Virtual Investor Day on March 6, 2026.

Published on: March 8, 2026